Cat. No.: HY-W011978

N-Acetyl-L-tryptophan

Customer Review

Based on 1 Customer Validation

N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases.

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 1218-34-4
Formula: C₁₃H₁₄N₂O₃
Molecular Weight:246.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

N-Acetyl-L-tryptophan Chemical Structure

CAS No.: 1218-34-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

NK1R

Caspase-1

IL-1β

All Endogenous Metabolite Isoforms :

All Neurokinin Receptor Isoforms :

All Caspase Isoforms :

All Interleukin Related Isoforms :

In Vitro

N-Acetyl-L-tryptophan (0.001–10 nM, 0.1–300 µM, 2 h) exhibits neuroprotective effects in a H₂O₂-induced amyotrophic lateral sclerosis model (cell lines: NSC-34 motoneurons and primary motor neurons.) induced by H₂O₂^[1].
N-Acetyl-L-tryptophan (30 μM, 15 min-6 h) inhibits the secretion of Substance P (HY-P0201) and lL-1β and the activation of caspase-1 in NSC-34 motoneurons^[1].
N-Acetyl-L-tryptophan (10 μM, 2 h) inhibits cell death in a H₂O₂-induced amyotrophic lateral sclerosis model by preventing the release of cytochrome c, Smac, and AIF from the mitochondria^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

H₂O₂-induced amyotrophic lateral sclerosis model (NSC-34 motoneurons and Primary motor neurons)
Concentration:

0.001, 0.01, 0.1, 1, 10 nM, 0.1, 1, 10, 30, 200, 300 μM
Incubation Time:

2 h
Result:

Significantly inhibited H₂O₂-induced cell death in NSC-34 motoneurons and primary motor neurons, with IC₅₀ values of 0.3 µM and 16 nM, respectively.

Western Blot Analysis^[1]

Cell Line:

H₂O₂-induced amyotrophic lateral sclerosis model (NSC-34 motoneurons)
Concentration:

10 μM
Incubation Time:

2 h
Result:

Effectively inhibited the release of cytochrome c/Smac/AIF from mitochondria into the cytoplasm.

In Vivo

N-Acetyl-L-tryptophan (10 mg/kg, i.p., single dose) confers hepatoprotection in an ischemia-reperfusion-induced Sprague-Dawley (SD) rat liver injury model by inhibiting excessive mitophagy^[3].
N-Acetyl-L-tryptophan (0.5 mg/kg, s.c., once daily for 21 days) reduces the incidence of L-DOPA (HY-N0304)-induced dyskinesia (LID) in the hemi-parkinsonian rodent model (Sprague-Dawley rats)^[3].
N-Acetyl-L-tryptophan (50 mg/kg, i.p., once daily for 28 days) can improve spatial memory deficits in the AlCl₃-induced Wistar rat dementia model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Ischemia-reperfusion-induced liver injury model in Sprague-Dawley (SD) rats (200-220 g)^[2]
Dosage:

10 mg/kg
Administration:

Intraperitoneal injection (i.p.), single dose
Result:

Reduced the expression of autophagy markers (Beclin1, LC3-II, ATG-7, and P62) in the ischemia-reperfusion-induced Sprague-Dawley (SD) rat liver injury model.

Animal Model:

L-DOPA (HY-N0304)-induced abnormal involuntary movements model in Spraguee Dawley rats(230-270 g, before L-DOPA induction, a hemi-parkinsonian model was created by Oxidopamine hydrobromide (HY-B1081A))
Dosage:

0.5 mg/kg
Administration:

Subcutaneous injection (s.c.), once daily for 21 days
Result:

Significantly reduced the onset of dyskinesia.

Chemical Information

CAS No. 1218-34-4
Appearance Solid
Molecular Weight 246.26
Formula C₁₃H₁₄N₂O₃
Color White to off-white
SMILES

O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (406.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0607 mL

20.3037 mL

40.6075 mL

5 mM

0.8121 mL

4.0607 mL

8.1215 mL

10 mM

0.4061 mL

2.0304 mL

4.0607 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sirianni A C, et al. N‐acetyl‐l‐tryptophan, but not N‐acetyl‐d‐tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis[J]. Journal of Neurochemistry, 2015, 134(5): 956-968. [Content Brief]

[2]. Li H, et al. Inhibition of excessive mitophagy by N-acetyl-L-tryptophan confers hepatoprotection against Ischemia-Reperfusion injury in rats[J]. PeerJ, 2020, 8: e8665. [Content Brief]

[3]. Thornton E, et al. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model[J]. Parkinsonism & related disorders, 2014, 20(5): 508-513. [Content Brief]

[4]. Fernandes J, et al. N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats[J]. Toxicology Mechanisms and Methods, 2018, 28(5): 328-334. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0607 mL	20.3037 mL	40.6075 mL	101.5187 mL
	5 mM	0.8121 mL	4.0607 mL	8.1215 mL	20.3037 mL
	10 mM	0.4061 mL	2.0304 mL	4.0607 mL	10.1519 mL
	15 mM	0.2707 mL	1.3536 mL	2.7072 mL	6.7679 mL
	20 mM	0.2030 mL	1.0152 mL	2.0304 mL	5.0759 mL
	25 mM	0.1624 mL	0.8121 mL	1.6243 mL	4.0607 mL
	30 mM	0.1354 mL	0.6768 mL	1.3536 mL	3.3840 mL
	40 mM	0.1015 mL	0.5076 mL	1.0152 mL	2.5380 mL
	50 mM	0.0812 mL	0.4061 mL	0.8121 mL	2.0304 mL
	60 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6920 mL
	80 mM	0.0508 mL	0.2538 mL	0.5076 mL	1.2690 mL
	100 mM	0.0406 mL	0.2030 mL	0.4061 mL	1.0152 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

N-Acetyl-L-tryptophan

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Pyroptosis Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Gut Microbial Metabolite Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Animal-Sourced Natural Product Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

3D Diverse Fragment Library

All Endogenous Metabolite Isoforms

All Neurokinin Receptor Isoforms

All Caspase Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

N-Acetyl-L-tryptophan Related Classifications

Cat. No.: HY-W011978